What is AOD-9604
AOD-9604 is a synthetic peptide corresponding to amino acids 176-191 of the human growth hormone (hGH) sequence, with phenylalanine at position 176 replaced by tyrosine. The name "AOD" originally stood for advanced obesity drug, reflecting its intended commercial application. The compound was developed by Professor Frank Ng at Monash University in Australia during the 1990s, and subsequently taken into clinical development by Metabolic Pharmaceuticals.
The Tyr176 substitution was not pharmacologically motivated. It was introduced to allow radioiodination for in vivo tracking studies and was retained throughout subsequent development. In the literature the compound appears as AOD9604, AOD-9604, hGH-(177-191), and occasionally hGH fragment 176-191, depending on whether the modified residue is counted as position 176 or 177. For clarity, this article uses "AOD-9604" throughout and treats it as distinct from the unmodified hGH fragment 176-191, though both cover the same functional C-terminal region.
The molecular weight of AOD-9604 is approximately 1817 Da. Its sequence lacks the N-terminal residues responsible for hGH receptor binding, which means it cannot trigger the somatotrophic axis. Browse the full compound catalog for related growth hormone axis peptides including CJC-1295, ipamorelin, and tesamorelin.
Mechanism: lipolysis without hGH receptor activation
Human growth hormone acts through two separable pathways. The GH receptor pathway drives IGF-1 release and promotes linear growth and cell proliferation. A distinct pathway, localized to the C-terminal region of the hGH molecule, regulates fat metabolism directly in adipose tissue. AOD-9604 contains this lipolytic domain but lacks the structural features that allow it to bind the GH receptor with meaningful affinity.
In vitro work showed AOD-9604 stimulates lipolysis in isolated adipocytes and inhibits lipogenesis, the storage of fatty acids as triglycerides. Critically, it does not compete with intact hGH for GH receptor binding, does not stimulate IGF-1 production, and does not induce cell proliferation in standard assays. This metabolic selectivity was the central pharmacological argument for its development.
The intracellular mechanism involves the beta-3 adrenergic receptor (beta3-AR), the main lipolytic receptor in rodent adipose tissue. A 2001 study by Heffernan et al. in Endocrinology (ob/ob and beta3-AR knock-out mice) showed that chronic AOD9604 treatment raised beta3-AR mRNA expression in adipose tissue and that the lipolytic response was abolished in beta3-AR knock-out animals. AOD-9604 does not appear to directly agonize beta3-AR; the upstream signal that raises receptor expression remains under investigation.
The downstream consequence of beta3-AR activation in adipose tissue is increased intracellular cAMP, which activates protein kinase A (PKA) and in turn phosphorylates hormone-sensitive lipase (HSL), the rate-limiting enzyme for triglyceride hydrolysis. AOD-9604's observed increase in lipolytic activity in adipose tissue is consistent with this pathway, though a direct measurement linking AOD-9604 to HSL phosphorylation has not been published in peer-reviewed literature as of 2026.
Preclinical evidence: what the animal studies show
The foundational preclinical work used C57Bl/6J ob/ob mice, a leptin-deficient model of genetic obesity. In 1994, Natera, Jiang, and Ng (Biochemistry and Molecular Biology International, ob/ob mice) demonstrated that chronic subcutaneous treatment with synthetic hGH 177-191 reduced cumulative body weight gain and adipose tissue mass. Lipogenesis in fat tissue was significantly inhibited, and the authors proposed the C-terminal region as the functional domain responsible for the anti-lipogenic actions of intact hGH.
Oral bioavailability was examined by Heffernan, Jiang, Thorburn, and Ng (American Journal of Physiology: Endocrinology and Metabolism, 2000, ob/ob mice). Obese mice given oral AOD-9401, a closely related D-Ala variant designed for oral stability, for 30 days showed significantly lower body weight gain from day 16 onward versus controls. Ex vivo analysis of adipose tissue confirmed reduced lipogenic activity and increased lipolytic activity.
A companion 2001 study in the International Journal of Obesity (Heffernan et al.) compared hGH and AOD9604 directly in obese mice, showing both compounds increased fat oxidation and produced weight loss, but only AOD9604 did so without altering glucose metabolism or insulin secretion. Human GH produced hyperglycemia at effective doses; AOD9604 did not, across all models tested.
All preclinical work used rodent models. No non-human primate data on AOD-9604 has been published. Extrapolation from ob/ob mouse studies is limited by the genetic nature of that obesity model, the leptin-deficiency background, and the substantially lower density of beta3-AR in human white adipose tissue compared to rodent fat. These differences are relevant context when reading the animal literature, though they do not diminish its mechanistic value for understanding the lipolytic pathway.
Human trial data: the OPTIONS trial and its outcome
Six human clinical studies were conducted with AOD-9604, spanning IV dosing pilots, oral dosing pilots, and two oral Phase 2b trials. The safety signal across all six was consistent: no significant adverse events, no IGF-1 elevation, no glucose or insulin perturbation. AOD-9604 did not interfere with the WADA hGH isoform test used in sports drug testing.
The definitive efficacy test was METAOD006, referred to as the OPTIONS trial. This Phase 2b study randomized 502 adults with obesity (BMI 30-45 kg/m2) to oral AOD-9604 at 0.25, 0.5, or 1 mg/day or placebo for 24 weeks, alongside a diet and exercise program. AOD-9604 did not separate from placebo on the primary weight loss endpoint at any dose. Metabolic Pharmaceuticals terminated its obesity development program in early 2007. The primary data were never submitted to a peer-reviewed journal.
The disconnect between animal and human data is the central scientific question left unresolved by the program. One candidate explanation: the ob/ob mouse model features complete leptin deficiency, which alters adipose tissue signaling in ways that may sensitize it to beta3-AR-mediated lipolysis. Human obesity rarely involves complete leptin absence. A second factor: the beta3-AR receptor has lower expression in human white adipose tissue than in rodent fat, making the pathway a weaker target in humans than preclinical results implied.
Regulatory and research status as of 2026
AOD-9604 has no approved therapeutic indication in any jurisdiction. Following the termination of the obesity program, Metabolic Pharmaceuticals pursued GRAS (Generally Recognized as Safe) designation for use of AOD-9604 in foods and dietary supplements. Self-affirmed GRAS status was granted on the basis of the existing human safety database, which covered over 800 subjects across oral dosing trials.
As of mid-2026, the FDA Pharmacy Compounding Advisory Committee (PCAC) has placed AOD-9604 in Category 2 for bulk drug substance review, meaning compounding is restricted pending further evaluation. This reflects the regulatory process for evaluating compounded substances with limited approved-use precedent rather than a specific safety finding. AOD-9604 is available as a research compound for in vitro and in vivo preclinical studies. Any human administration outside of an approved clinical trial would be off-label and unregulated.
Some recent research has examined AOD-9604 in cartilage repair models, separate from its original lipolytic application. These studies are preliminary and animal-based; no clinical data on cartilage indications exist as of 2026.
Storage and handling for research use
AOD-9604 for research is supplied as a lyophilized powder in sealed vials. The lyophilized form is stable at -20°C or below for the manufacturer's stated shelf life, typically 24 months from production. Once reconstituted with bacteriostatic water (see the peptide storage guide), solution stability drops considerably: most stability data support use within 28 to 30 days when refrigerated at 2-8°C.
Researchers in Indonesia face above-average thermal exposure during last-mile courier transit, particularly outside Jakarta and Bali where air-conditioned logistics are less reliable. Lyophilized vials are substantially more resilient to transit temperature spikes than reconstituted solutions. Aliquoting before freezing avoids repeated freeze-thaw cycles, which accelerate hydrolysis in reconstituted peptides. For concentration calculations and reconstitution math, the dosing calculator covers the standard mg/ml to mcg/unit conversions.